Top in endocrinology: CVD and diabetes risks after COVID-19; disparities in obesity
Click Here to Manage Email Alerts
COVID-19 was not associated with long-term increased risks for CVD or diabetes, according to findings from a population-based cohort study conducted in the United Kingdom.
Researchers reported that the increased risk for CVD in people infected with SARS-CoV-2 began to decline 5 weeks after infection, and the increased risk for diabetes dropped 23 weeks after infection. It was the top story in endocrinology last week.
Another top story was an in-depth look at how genetics and racism contribute to racial and ethnic disparities in obesity and comorbidities.
Read these and more top stories in endocrinology below:
COVID-19 not linked to increased long-term risk for CVD or diabetes
People infected with COVID-19 do not have increased long-term risks for developing cardiovascular disease or diabetes, according to a study published in PLOS Medicine. Read more.
Genetics and racism contribute to racial-ethnic disparities in obesity and comorbidities
Obesity prevalence is on the rise across the U.S., but some groups are at a greater risk for the disease than others. Read more.
Low testosterone level increases mortality risk for men hospitalized with COVID-19
Men hospitalized with COVID-19 with a serum total testosterone of less than 3.9 nmol/L have a greater risk for death compared with those with higher testosterone levels, according to study data. Read more.
Better overnight time in range, worse sleep quality with closed-loop insulin delivery
Older adults with type 1 diabetes using hybrid closed-loop insulin pump therapy had more time in range during sleep, but worse sleep quality compared with those using sensor-augmented therapy, according to study findings. Read more.
TSH, TRAb positivity associated with rebound Graves’ hyperthyroidism in early pregnancy
For pregnant women with well-controlled Graves’ hyperthyroidism, subnormal thyroid-stimulating hormone levels and thyrotropin-receptor antibody positivity at drug withdrawal were linked to a rebound of Graves’ hyperthyroidism. Read more.